What Makes BioMarin (BMRN) so Attractive

As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish expert sentiment. Of the 15 analysts covering the stock, 10 assigned Buy ratings and 5 issued Hold ratings. With nary Sell rating, the banal has a projected median 1-year terms people of $88.29, implying much than 47% upside.

Copyright: nexusplexus / 123RF Stock Photo

On February 6, Allison Bratzel from Piper Sandler reiterated her Overweight standing connected BioMarin Pharmaceutical (NASDAQ:BMRN). The expert reduced her terms people connected the banal from $122 to $84. Despite this downward revision, her estimates inactive connote upside imaginable of much than 40% from the prevailing level. Bratzel’s standing incorporates caller fourth-quarter pre-releases, which besides prompted Piper Sandler to set its estimates and terms targets for immoderate commercialized names.

BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes targeted therapies for life-threatening aesculapian conditions and uncommon familial diseases. Some of its large products see VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME. The institution operates successful much than 70 countries and presently has respective drugs successful the improvement stage.

While we admit the imaginable of BMRN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.